Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: Disappointing results

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Oze, Isao ^a   Hotta, Katsuyuki ^a   Kiura, Katsuyuki ^a   Ochi, Nobuaki ^a   Takigawa, Nagio ^a   Fujiwara, Yoshiro ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY; VALIDITY; LUNG TUMOR; REGRESSION ANALYSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VINCRISTINE;

EID: 70649099227     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007835     Document Type: Article

References (24)

1. Smyth JF (1989) Chemotherapy of small cell lung cancer. Chest 96: 61S-62S.
2. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, et al. (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282-291.
3. Chute JP, Chen T, Feigal E, Simon R, Johnson BE (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17: 1794-1801.
4. Stahel RA (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5.
5. Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4: 31-42.
6. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, et al. (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357: 664-672.
7. Ihde DC (1995) Small cell lung cancer. State-of-the-art therapy 1994. Chest 107: 243S-248S.
8. Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, et al. (2008) Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 99: 442-447.
9. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, et al. (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855-861.
10. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, et al. (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20: 4665-4672.
11. Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, et al. (2006) Openlabel, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24: 2044-2051.
12. Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T Jr, et al. (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24: 2038-2043.
13. Heigener DF, Freitag L, Eschbach C, Huber RM, Fink T, et al. (2008) Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): Final results of a randomised phase III trial. 2008 May 20.
14. Lara PN, Jr., Natale R, Crowley J, Lenz HJ, Redman MW, et al. (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/ cisplatin in extensivestage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27: 2530-2535.
15. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC (2007) Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12: 1096-1104.
16. Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, et al. (2007) Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 109: 939-948.
17. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, et al. (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631.
18. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, et al. (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22: 254-261.
19. Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, et al. (2005) Sequential versus alternating administration of cisplatin/ etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Clin Lung Cancer 7: 183-189.
20. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Oze I, et al. (2009) Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 20: 829-834.
21. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91.
22. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. (2007) The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2: 1067-1077.
23. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, et al. (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26: 5401-5406.
24. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, et al. (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17: 658-667.